Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice

Journal of Translational Medicine

Volumn 13, Issue 1, 2015, Pages

  Ganz, Michal ^a   Bukong, Terence N ^a   Csak, Timea ^a   Saha, Banishree ^a   Park, Jin Kyu ^a   Ambade, Aditya ^a   Kodys, Karen ^a   Szabo, Gyongyi ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Danger signals; High fat diet with high cholesterol and a high sugar supplement (HF HC HSD); Inflammasome; Non alcoholic steatohepatitis (NASH); Tumor

Indexed keywords

HIGH MOBILITY GROUP B1 PROTEIN; INSULIN; INTERLEUKIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA; AUTACOID; BIOLOGICAL MARKER; CARBOHYDRATE DIET; CHOLESTEROL; CYTOKINE; INFLAMMASOME;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CELL DIFFERENTIATION; CHOLESTEROL DIET; CYTOKINE PRODUCTION; DISEASE COURSE; HEPATITIS; INSULIN BLOOD LEVEL; LIPID DIET; LIVER FIBROSIS; LIVER SIZE; LIVER TUMOR; MACROPHAGE; MACROPHAGE ACTIVATION; MALE; MONOCYTE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PATHOGENESIS; PHENOTYPE; POLARIZATION; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SUGAR INTAKE; UPREGULATION; ADVERSE EFFECTS; ANIMAL; C57BL MOUSE; CARBOHYDRATE DIET; COMPLICATION; DISEASE MODEL; FEEDING BEHAVIOR; FEMALE; INFLAMMATION; KUPFFER CELL; LIVER; LIVER CIRRHOSIS; METABOLISM; ORGAN SIZE; PATHOLOGY; TIME FACTOR;

ANIMALS; BIOMARKERS; BODY WEIGHT; CHOLESTEROL; CYTOKINES; DIET, HIGH-FAT; DIETARY CARBOHYDRATES; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FEEDING BEHAVIOR; FEMALE; INFLAMMASOMES; INFLAMMATION; INFLAMMATION MEDIATORS; INSULIN; KUPFFER CELLS; LIVER; LIVER CIRRHOSIS; LIVER NEOPLASMS; MACROPHAGE ACTIVATION; MALE; MICE, INBRED C57BL; NON-ALCOHOLIC FATTY LIVER DISEASE; ORGAN SIZE; TIME FACTORS; UP-REGULATION;

EID: 84931272963     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/s12967-015-0552-7     Document Type: Article

References (58)

1. Ng M, Fleming T, Robinson M, Thomson B, Graetz N, Margono C et al (2014) Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 384:766-781
2. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K et al (2012) The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 142:1592-1609
3. Tiniakos DG, Vos MB, Brunt EM (2010) Nonalcoholic fatty liver disease: pathology and pathogenesis. Annu Rev Pathol 5:145-171
4. Tarantino G, Savastano S, Colao A (2010) Hepatic steatosis, low-grade chronic inflammation and hormone/growth factor/adipokine imbalance. World J Gastroenterol 16:4773-4783
5. Sheth SG, Gordon FD, Chopra S (1997) Nonalcoholic steatohepatitis. Ann Intern Med 126:137-145
6. Shimada M, Hashimoto E, Taniai M, Hasegawa K, Okuda H, Hayashi N et al (2002) Hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. J Hepatol 37:154-160
7. Corrado RL, Torres DM, Harrison SA (2014) Review of treatment options for nonalcoholic fatty liver disease. Med Clin N Am 98:55-72
8. Eguchi A, Povero D, Alkhouri N, Feldstein AE (2013) Novel therapeutic targets for nonalcoholic fatty liver disease. Exp Opin Ther Targets 17:773-779
9. Wong VW, Wong GL, Choi PC, Chan AW, Li MK, Chan HY et al (2010) Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. Gut 59:969-974
10. Vernon G, Baranova A, Younossi ZM (2011) Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 34:274-285
11. Pais R, Pascale A, Fedchuck L, Charlotte F, Poynard T, Ratziu V (2011) Progression from isolated steatosis to steatohepatitis and fibrosis in nonalcoholic fatty liver disease. Clin Res Hepatol Gastroenterol 35:23-28
12. Fassio E, Alvarez E, Dominguez N, Landeira G, Longo C (2004) Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies. Hepatology 40:820-826
13. Harrison SA, Torgerson S, Hayashi PH (2003) The natural history of nonalcoholic fatty liver disease: a clinical histopathological study. Am J Gastroenterol 98:2042-2047
14. Sorrentino P, Tarantino G, Conca P, Perrella A, Terracciano ML, Vecchione R et al (2004) Silent non-alcoholic fatty liver disease-a clinical-histological study. J Hepatol 41:751-757
15. Schuppan D, Schattenberg JM (2013) Non-alcoholic steatohepatitis: pathogenesis and novel therapeutic approaches. J Gastroenterol Hepatol 28(Suppl 1):68-76
16. Hashimoto E, Yatsuji S, Kaneda H, Yoshioka Y, Taniai M, Tokushige K et al (2005) The characteristics and natural history of Japanese patients with nonalcoholic fatty liver disease. Hepatol Res 33:72-76
17. White DL, Kanwal F, El-Serag HB (2012) Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clin Gastroenterol Hepatol 10(1342-1359):e2
18. Nakamura A, Tajima K, Zolzaya K, Sato K, Inoue R, Yoneda M et al (2012) Protection from non-alcoholic steatohepatitis and liver tumourigenesis in high fat-fed insulin receptor substrate-1-knockout mice despite insulin resistance. Diabetologia 55:3382-3391
19. Kohli R, Kirby M, Xanthakos SA, Softic S, Feldstein AE, Saxena V et al (2010) High-fructose, medium chain trans fat diet induces liver fibrosis and elevates plasma coenzyme Q9 in a novel murine model of obesity and nonalcoholic steatohepatitis. Hepatology 52:934-944
20. Kanuri G, Bergheim I (2013) In vitro and in vivo models of non-alcoholic fatty liver disease (NAFLD). Int J Mol Sci 14:11963-11980
21. Ganz M, Csak T, Szabo G (2014) High fat diet feeding results in gender specific steatohepatitis and inflammasome activation. World J Gastroenterol 20:8525-8534
22. Csak T, Ganz M, Pespisa J, Kodys K, Dolganiuc A, Szabo G (2011) Fatty acid and endotoxin activate inflammasomes in mouse hepatocytes that release danger signals to stimulate immune cells. Hepatology 54:133-144
23. Csak T, Pillai A, Ganz M, Lippai D, Petrasek J, Park J-K et al (2014) Both bone marrow-derived and non-bone marrow-derived cells contribute to AIM2 and NLRP3 inflammasome activation in a MyD88-dependent manner in dietary steatohepatitis. Liver Int 34:1402-1413
24. Martinon F, Burns K, Tschopp J (2002) The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell 10:417-426
25. Petrasek J, Bala S, Csak T, Lippai D, Kodys K, Menashy V et al (2012) IL-1 receptor antagonist ameliorates inflammasome-dependent alcoholic steatohepatitis in mice. J Clin Invest 122:3476-3489
26. Lippai D, Bala S, Petrasek J, Csak T, Levin I, Kurt-Jones EA et al (2013) Alcohol-induced IL-1beta in the brain is mediated by NLRP3/ASC inflammasome activation that amplifies neuroinflammation. J Leukoc Biol 94:171-182
27. Velayudham A, Hritz I, Dolganiuc A, Mandrekar P, Kurt-Jones E, Szabo G (2006) Critical role of toll-like receptors and the common TLR adaptor, MyD88, in induction of granulomas and liver injury. J Hepatol 45:813-824
28. Guy CD, Suzuki A, Zdanowicz M, Abdelmalek MF, Burchette J, Unalp A et al (2012) NASH CRN: hedgehog pathway activation parallels histologic severity of injury and fibrosis in human nonalcoholic fatty liver disease. Hepatology 55:1711-1721
29. Marra F, DeFranco R, Grappone C, Milani S, Pastacaldi S, Pinzani M et al (1998) Increased expression of monocyte chemotactic protein-1 during active hepatic fibrogenesis: correlation with monocyte infiltration. Am J Pathol 152:423-430
30. Baeck C, Wehr A, Karlmark KR, Heymann F, Vucur M, Gassler N et al (2012) Pharmacological inhibition of the chemokine CCL2 (MCP-1) diminishes liver macrophage infiltration and steatohepatitis in chronic hepatic injury. Gut 61:416-426
31. Lamkanfi M, Dixit VM (2012) Inflammasomes and their roles in health and disease. Annu Rev Cell Dev Biol 28:137-161
32. Ciraci C, Janczy JR, Sutterwala FS, Cassel SL (2012) Control of innate and adaptive immunity by the inflammasome. Microbes Infect 14:1263-1270
33. Szabo G, Csak T (2012) Inflammasomes in liver diseases. J Hepatol 57:642-654
34. Kubes P, Mehal WZ (2012) Sterile inflammation in the liver. Gastroenterology 143:1158-1172
35. Rivera CA, Adegboyega P, van Rooijen N, Tagalicud A, Allman M, Wallace M (2007) Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis. J Hepatol 47:571-579
36. Tosello-Trampont AC, Landes SG, Nguyen V, Novobrantseva TI, Hahn YS (2012) Kuppfer cells trigger nonalcoholic steatohepatitis development in diet-induced mouse model through tumor necrosis factor-alpha production. J Biol Chem 287:40161-40172
37. Gordon S, Taylor PR (2005) Monocyte and macrophage heterogeneity. Nat Rev Immunol 5:953-964
38. Deng ZB, Liu Y, Liu C, Xiang X, Wang J, Cheng Z et al (2009) Immature myeloid cells induced by a high-fat diet contribute to liver inflammation. Hepatology 50:1412-1420
39. Ma X, Hua J, Li Z (2008) Probiotics improve high fat diet-induced hepatic steatosis and insulin resistance by increasing hepatic NKT cells. J Hepatol 49:821-830
40. Tajiri K, Shimizu Y (2012) Role of NKT cells in the pathogenesis of NAFLD. Int J Hepatol 2012:850836
41. Mosser DM (2003) The many faces of macrophage activation. J Leukoc Biol 73:209-212
42. Iredale JP (2007) Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ. J Clin Invest 117:539-548
43. Pellicoro A, Ramachandran P, Iredale JP, Fallowfield JA (2014) Liver fibrosis and repair: immune regulation of wound healing in a solid organ. Nat Rev Immunol 14:181-194
44. Micchelli ST, Vivekanandan P, Boitnott JK, Pawlik TM, Choti MA, Torbenson M (2008) Malignant transformation of hepatic adenomas. Mod Pathol 21:491-497
45. Bioulac-Sage P, Sempoux C, Possenti L, Frulio N, Laumonier H, Laurent C et al (2013) Pathological diagnosis of hepatocellular cellular adenoma according to the clinical context. Int J Hepatol 2013:253261
46. Kuhlmann WD, Peschke P (2006) Hepatic progenitor cells, stem cells, and AFP expression in models of liver injury. Int J Exp Pathol 87:343-359
47. Sell S (2008) Alpha-fetoprotein, stem cells and cancer: how study of the production of alpha-fetoprotein during chemical hepatocarcinogenesis led to reaffirmation of the stem cell theory of cancer. Tumour Biol 29:161-180
48. Clapper JR, Hendricks MD, Gu G, Wittmer C, Dolman CS, Herich J et al (2013) Diet-induced mouse model of fatty liver disease and nonalcoholic steatohepatitis reflecting clinical disease progression and methods of assessment. Am J Physiol Gastrointest Liver Physiol 305:G483-G495
49. Tetri LH, Basaranoglu M, Brunt EM, Yerian LM, Neuschwander-Tetri BA (2008) Severe NAFLD with hepatic necroinflammatory changes in mice fed trans fats and a high-fructose corn syrup equivalent. Am J Physiol Gastrointest Liver Physiol 295:G987-G995
50. Charlton M, Krishnan A, Viker K, Sanderson S, Cazanave S, McConico A et al (2011) Fast food diet mouse: novel small animal model of NASH with ballooning, progressive fibrosis, and high physiological fidelity to the human condition. Am J Physiol Gastrointest Liver Physiol 301:G825-G834
51. Nath B, Levin I, Csak T, Petrasek J, Mueller C, Kodys K et al (2011) Hepatocyte-specific hypoxia-inducible factor-1alpha is a determinant of lipid accumulation and liver injury in alcohol-induced steatosis in mice. Hepatology 53:1526-1537
52. Mandrekar P, Ambade A, Lim A, Szabo G, Catalano D (2011) An essential role for monocyte chemoattractant protein-1 in alcoholic liver injury: regulation of proinflammatory cytokines and hepatic steatosis in mice. Hepatology 54:2185-2197
53. Terada K, Yamada J, Hayashi Y, Wu Z, Uchiyama Y, Peters C et al (2010) Involvement of cathepsin B in the processing and secretion of interleukin-1beta in chromogranin A-stimulated microglia. Glia 58:114-124
54. Day CP, James OF (1998) Steatohepatitis: a tale of two "hits"? Gastroenterology 114:842-845
55. Tilg H, Moschen AR (2010) Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 52:1836-1846
56. Wan J, Benkdane M, Teixeira-Clerc F, Bonnafous S, Louvet A, Lafdil F et al (2014) M2 Kupffer cells promote M1 Kupffer cell apoptosis: a protective mechanism against alcoholic and nonalcoholic fatty liver disease. Hepatology 59:130-142
57. Iredale JP, Thompson A, Henderson NC (2013) Extracellular matrix degradation in liver fibrosis: biochemistry and regulation. Biochim Biophys Acta 1832:876-883
58. Mormone E, George J, Nieto N (2011) Molecular pathogenesis of hepatic fibrosis and current therapeutic approaches. Chem Biol Interact 193:225-231